查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866606

Duchenne氏肌肉失養症（DMD）治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 92 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球Duchenne氏肌肉失養症(DMD) 治療市場規模估計為 21.7 億美元，預計到 2031 年將達到 47.76 億美元，在預測期（2025-2031 年）內以 13.1% 的複合年成長率成長。

Duchenne氏肌肉失養症（DMD 或簡稱杜氏肌肉營養不良）是一種罕見的遺傳性疾病。它主要影響男性，但在極少數情況下也會影響女性。隨著時間的推移，Duchenne氏肌肉失養症會導致身體肌肉逐漸衰弱和受損，最終導致死亡。導致Duchenne氏肌肉失養症的基因改變（DMD 基因突變）發生在出生前，可以是遺傳性的，也可以是基因自發性新發生突變的結果。肌肉無力通常在 3 至 5 歲之間開始顯現，大多數患者在 12 歲時就需要依靠輪椅出行。青春期時，心臟和呼吸肌肉會逐漸衰弱，導致嚴重的、危及生命的併發症。

Duchenne氏肌肉失養症（DMD）治療市場主要受以下因素驅動：

一、疾病負擔與未滿足的需求

高致殘率和死亡率：

杜氏肌肉營養不良症（DMD）是一種進行性肌肉萎縮疾病。患者通常在10歲左右喪失行走能力，並在20至30歲之間死於心肺衰竭。全球已通報約30萬例病例，其中中國超過7萬例，對社會造成了沉重的負擔。

如果女性帶因者生下男孩，男孩有 50% 的幾率遺傳這種疾病，使得家族患病的風險非常高。

現有治療方法的限制：

目前主要的治療方法是皮質類固醇（例如，地夫可特）和局部外顯子跳躍藥物（例如，Exondys51），可以延緩疾病進展，但不能治愈，需要長期使用，並且伴隨嚴重的副作用。

由於它只適用於特定的基因突變類型（例如外顯子 51/53 跳躍），因此符合治療條件的患者群體有限，缺乏通用治療方法。

提高診斷率：

隨著醫療基礎設施的發展和都市化的進步，預計到 2025 年，中國 DMD 的診斷率將從 2022 年的約 30% 上升到 50% 以上，這意味著將有更多的患者加入需要治療的群體中。

二、研發進度及在研發突破

基因療法和寡核苷酸技術的突破：

在基因治療領域，已開發出一些只需單次給藥即可實現長期蛋白表達的治療方法，例如Sarepta公司的SRP-9001（使用AAVrh74載體遞送微型Dystrophin）和Faith Pharmaceuticals公司的BBM-D101（改良AAV載體）。臨床試驗證實，陽性肌纖維的比例顯著增加。

匯達基因的 CRISPR-Cas12 基因編輯療法已進入臨床試驗階段，目標是修復基因突變。

寡核苷酸療法，包括反義寡核苷酸 (ASO) 和下一代胜肽連接寡核苷酸 (PPMO)，如 Pepgen 的 PGN-EDO51 和 Entrada 的 ENTR-601-44，增強了細胞攝取和溶酶體逃逸，提高了療效並降低了劑量。

日本活躍的開發平臺：

目前中國有十餘種用於治療杜氏肌肉營養不良症（DMD）的藥物正在進行臨床試驗，包括基因編輯療法（例如匯大基因的CRISPR-Cas12）、腺相關病毒（AAV）基因療法（例如金威生物的JWK007）和微蛋白藥物（例如信德醫藥的BBM-D101）。部分藥物已獲得美國食品藥物管理局（FDA）的孤兒藥資格認定，預計2026年後上市。

三、政策支持與支付環境最佳化

對罕見疾病的政策支持：

美國：DUX 法案將 DMD 孤兒藥的市場獨佔期延長至 7.5 年，加速核准將上市時間縮短了 34%。

中國：杜氏肌肉營養不良症（DMD）將被列入2024年第二批罕見疾病名錄，這將促進國內相關研究和發展。健保覆蓋範圍將擴大，瓦莫羅酮已被納入國家健保談判。預計到2026年，國產基因治療藥物的價格將降至200萬元以下。

成本效益提高：

北美：像聯合健康保險公司這樣的私人保險公司優先承保杜氏肌肉營養不良症基因療法，承保率超過 80%。在歐洲，透過衛生技術評估的產品的報銷率超過 80%，但產品上市時間比美國晚 9 到 15 個月。

亞太地區：中國、日本和韓國等市場正在經歷顯著成長，相關政策和資本為獲得治療提供了便利。

DMD治療市場的發展受疾病嚴重、技術突破和有利政策的驅動。基因編輯和RNA療法有望主導市場，但高成本和產能瓶頸（例如AAV載體的生產）仍然是亟待克服的挑戰。各公司必須專注於技術創新和最佳化支付模式，以滿足尚未滿足的醫療需求。

本報告旨在依地區/國家、類型和應用對全球Duchenne氏肌肉失養症(DMD) 治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以收益為準，以2024年為基準年，對Duchenne氏肌肉失養症（DMD）治療藥物市場規模、估算和預測進行了分析，並涵蓋了2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定業務/成長策略、評估市場競爭、分析自身在當前市場中的地位，並就Duchenne氏肌肉失養症（DMD）治療藥物做出明智的商業決策。

市場區隔

公司

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

依類型分類的區隔市場

  • 埃克森迪斯
  • 姆弗拉扎
  • 特蘭斯拉納

應用領域

  • 醫院
  • 診所
  • 居家醫療

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Duchenne Muscular Dystrophy (DMD) Therapeutics was estimated to be worth US$ 2170 million in 2024 and is forecast to a readjusted size of US$ 4776 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne-a mutation in the DMD gene-happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:

I. Disease Burden and Unmet Needs

High Disability and Mortality Rates:

DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:

Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population.

Improved Diagnosis Rate:

With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs

Breakthroughs in Gene Therapy and Oligonucleotide Technologies:

Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage.

Active Domestic R&D Pipeline:

Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment

Policy Support for Rare Diseases:

US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:

North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics by region & country, by Type, and by Application.

The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.

Market Segmentation

By Company

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Segment by Type

  • Exondys
  • Emflaza
  • Translarna

Segment by Application

  • Hospitals
  • Clinics
  • Home Care

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Introduction
  • 1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2020-2031)
  • 1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends & Drivers
    • 1.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
    • 1.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
    • 1.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
    • 1.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024)
  • 2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025)
  • 2.3 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
  • 2.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis
    • 2.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exondys
    • 3.1.2 Emflaza
    • 3.1.3 Translarna
  • 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type
    • 3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2020-2031)
    • 3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Home Care
  • 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application
    • 4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2020-2031)
    • 4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region
    • 5.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025)
    • 5.1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031)
    • 5.1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.5.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.5.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.6.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.7.2 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.9.2 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Sarepta Therapeutics
    • 7.1.1 Sarepta Therapeutics Profile
    • 7.1.2 Sarepta Therapeutics Main Business
    • 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Sarepta Therapeutics Recent Developments
  • 7.2 PTC Therapeutics
    • 7.2.1 PTC Therapeutics Profile
    • 7.2.2 PTC Therapeutics Main Business
    • 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PTC Therapeutics Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Bristol-Myers Squibb Profile
    • 7.4.2 Bristol-Myers Squibb Main Business
    • 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bristol-Myers Squibb Recent Developments
  • 7.5 Italfarmaco
    • 7.5.1 Italfarmaco Profile
    • 7.5.2 Italfarmaco Main Business
    • 7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Italfarmaco Recent Developments
  • 7.6 Santhera Pharmaceuticals
    • 7.6.1 Santhera Pharmaceuticals Profile
    • 7.6.2 Santhera Pharmaceuticals Main Business
    • 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Santhera Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
  • 8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
  • Table 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
  • Table 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
  • Table 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
  • Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
  • Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Sarepta Therapeutics Basic Information List
  • Table 32. Sarepta Therapeutics Description and Business Overview
  • Table 33. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Sarepta Therapeutics (2020-2025)
  • Table 35. Sarepta Therapeutics Recent Developments
  • Table 36. PTC Therapeutics Basic Information List
  • Table 37. PTC Therapeutics Description and Business Overview
  • Table 38. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of PTC Therapeutics (2020-2025)
  • Table 40. PTC Therapeutics Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. Bristol-Myers Squibb Basic Information List
  • Table 47. Bristol-Myers Squibb Description and Business Overview
  • Table 48. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Bristol-Myers Squibb (2020-2025)
  • Table 50. Bristol-Myers Squibb Recent Developments
  • Table 51. Italfarmaco Basic Information List
  • Table 52. Italfarmaco Description and Business Overview
  • Table 53. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Italfarmaco (2020-2025)
  • Table 55. Italfarmaco Recent Developments
  • Table 56. Santhera Pharmaceuticals Basic Information List
  • Table 57. Santhera Pharmaceuticals Description and Business Overview
  • Table 58. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Santhera Pharmaceuticals (2020-2025)
  • Table 60. Santhera Pharmaceuticals Recent Developments
  • Table 61. Key Raw Materials Lists
  • Table 62. Raw Materials Key Suppliers Lists
  • Table 63. Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Customers
  • Table 64. Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors List
  • Table 65. Research Programs/Design for This Report
  • Table 66. Key Data Information from Secondary Sources
  • Table 67. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
  • Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
  • Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
  • Figure 7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Exondys Picture
  • Figure 9. Emflaza Picture
  • Figure 10. Translarna Picture
  • Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Hospitals
  • Figure 14. Product Picture of Clinics
  • Figure 15. Product Picture of Home Care
  • Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (%), (2020-2031)
  • Figure 29. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
  • Figure 51. Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed